872365-14-5

Basic information

• Product Name: Fevipiprant
• Synonyms: Fevipiprant;Fevipipran;NVP-QAW039;Fevipiprant(NVP-QAW039);QAW039;Fevipiprant (QAW039);2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid
• CAS NO: 872365-14-5
• Molecular Formula: C19H17F3N2O4S
• Molecular Weight: 426.4094896
• Mol File: 872365-14-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 637.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: 3.33±0.30(Predicted)
• CAS DataBase Reference: Fevipiprant(CAS DataBase Reference)
• NIST Chemistry Reference: Fevipiprant(872365-14-5)
• EPA Substance Registry System: Fevipiprant(872365-14-5)

Safety Data

• Hazardous Substances Data: 872365-14-5(Hazardous Substances Data)

Usage

Uses

Fevipiprant is used in the oral treatment of asthma and has been successful in targeting severe eosinophilic asthma.Fevipiprant is a novel oral prostaglandin D2 receptor 2 (DP2; known as CRTh2) antagonist and currently in development for the treatment of severe asthma and atopic dermatitis.

Upstream product

• 13972-76-4 diethyl 3-acetylglutarate 
• 41436-95-7 dimethyl 3-acetylglutarate 
• 504-29-0 2-aminopyridine 
• 933717-06-7 2-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid 
• 6302-03-0 1-(pyridin-3-yl)-2-propanone 
• 921-84-6 2-cyano-3-oxobutyric acid ethyl ester 
• 7546-50-1 2-(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid 

Relevant articles and documents

Using a Johnson-Claisen Rearrangement Strategy to Construct Azaindoles – A Streamlined and Concise Route for the Commercial Process of Fevipiprant

A novel and concise synthesis of the DP2 receptor antagonist Fevipiprant (NVP-QAW039) was developed. The initial research route was suffering from a long reaction sequence to the functionalized 7-aza-indole core followed by a poorly selective N(1)-alkylat

PREPARATION OF 2-[2-METHYL-1-[[4-METHYLSULFONYL-2-(TRIFLUORO METHYL)PHENYL]METHYL] PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID

The present invention relates to a novel compound of Formula IV and use of said compound for the preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl] methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid [fevipiprant], Formula IV wherein A is SO2Me, halogen or a leaving group. The present invention further relates to a process of preparation of pharmaceutical acceptable salts of fevipiprant and composition thereof.

Concise synthetic method of asthma drug Fevipiprant

The invention discloses a concise synthetic method of asthma drug Fevipiprant. The concise synthetic method of asthma drug Fevipiprant comprises a following step: a compound 4 is reacted so as to obtain Fevipiprant. According to the concise synthetic method, 1-(3-pyridyl)-2-acetone is taken as a raw material, a pyridine nitrogen oxide is generated through oxidation, a 7-azaindole mother nucleus isobtained under mild conditions. The step number of the concise synthetic method are few, the technology is simple, reaction conditions are mild, production cost is low, no transition metal catalysisis needed, no protective group is needed in the whole synthesis process, and a relatively simple four step Fevipiprant preparation method is invented.